Ann Pediatr Endocrinol Metab.  2017 Mar;22(1):60-64. 10.6065/apem.2017.22.1.60.

Diabetes mellitus caused by secondary hemochromatosis after multiple blood transfusions in 2 patients with severe aplastic anemia

Affiliations
  • 1Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. hwyoo@amc.seoul.kr

Abstract

Hemochromatosis is an inherited or secondary disorder caused by excessive iron storage leading to multiple organ damage. We describe 2 patients with diabetes mellitus caused by hemochromatosis secondary to multiple blood transfusions due to severe aplastic anemia. Subject 1, who was diagnosed with severe aplastic anemia at 15 years of age, received multiple red blood cell transfusions before he underwent autologous peripheral blood stem cell transplantation (PBSCT) at 22 years of age. At 21 years of age, hyperglycemia was detected with increased hemoglobin A1c and serum ferritin levels, 9.7% and 12,910 ng/mL (normal range, 20-320 ng/mL), respectively. The 24-hour urine C-peptide level was normal with negative antiglutamic acid decarboxylase antibody. Subsequently, metformin and an iron-chelating agent were administered. However, an intensive insulin regimen was necessary 2 years after the onset of diabetes. Subject 2, who was diagnosed with severe aplastic anemia at 2 years of age, received multiple blood transfusions until she underwent haploidentical PBSCT at 13 years of age. At 11 years of age, she developed diabetes mellitus with a high serum ferritin level (12,559.8 ng/mL). She is currently 18 years old and has been treated with an intensive insulin regimen and estrogen/progesterone replacement therapy because of hypogonadotropic hypogonadism. It is presumed that the loss of insulin secretory capacity and insulin resistance played a role in the pathogenesis of diabetes mellitus due to hemochromatosis in these cases.

Keyword

Aplastic anemia; Diabetes; Hemochromatosis

MeSH Terms

Anemia, Aplastic*
Blood Transfusion*
C-Peptide
Diabetes Mellitus*
Erythrocyte Transfusion
Ferritins
Hemochromatosis*
Humans
Hyperglycemia
Hypogonadism
Insulin
Insulin Resistance
Iron
Metformin
Peripheral Blood Stem Cell Transplantation
C-Peptide
Ferritins
Insulin
Iron
Metformin

Figure

  • Fig. 1 Glycated hemoblogin A1c (HbA1c) and ferritin levels of the 2 patients. (A) Case 1, (B) case 2. PBSCT, peripheral blood stem cell transplantation.


Cited by  1 articles

Long-term endocrine sequelae after hematopoietic stem cell transplantation in children and adolescents
Soojin Hwang, Yena Lee, Ji-Hee Yoon, Ja Hye Kim, Hyery Kim, Kyung-Nam Koh, Ho Joon Im, Han-Wook Yoo, Jin-Ho Choi
Ann Pediatr Endocrinol Metab. 2024;29(2):109-118.    doi: 10.6065/apem.2346046.023.


Reference

1. Burt MJ, George DK, Powell LW. Haemochromatosis: a clinical update. Med J Aust. 1996; 164:348–351. PMID: 8606660.
2. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med. 1981; 304:319–324. PMID: 6777701.
Article
3. Hahn JU, Steiner M, Bochnig S, Schmidt H, Schuff-Werner P, Kerner W. Evaluation of a diagnostic algorithm for hereditary hemochromatosis in 3,500 patients with diabetes. Diabetes Care. 2006; 29:464–466.
Article
4. Kim MK, Lee JW, Baek KH, Song KH, Kwon HS, Oh KW, et al. Endocrinopathies in transfusion-associated iron overload. Clin Endocrinol (Oxf). 2013; 78:271–277. PMID: 22788934.
Article
5. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford (CA): Stanford University Press;1959.
6. Creighton Mitchell T, McClain DA. Diabetes and hemochromatosis. Curr Diab Rep. 2014; 14:488. PMID: 24682660.
Article
7. McClain DA, Abraham D, Rogers J, Brady R, Gault P, Ajioka R, et al. High prevalence of abnormal glucose homeostasis secondary to decreased insulin secretion in individuals with hereditary haemochromatosis. Diabetologia. 2006; 49:1661–1669. PMID: 16538487.
Article
8. Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G, et al. Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia. Klin Padiatr. 2010; 222:399–406. PMID: 20862634.
Article
9. Rotaru I, Gaman A, Gaman G. Secondary haemochromatosis in a patient with thalassemia intermedia. Curr Health Sci J. 2014; 40:67–70. PMID: 24791210.
10. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013; 93:1721–1741. PMID: 24137020.
Article
11. Hartmann J, Braulke F, Sinzig U, Wulf G, Maas JH, Konietschke F, et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013; 37:327–332. PMID: 23259989.
Article
12. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2008; 6(Suppl 1):158–169. PMID: 19337172.
13. Zhao Z, Li S, Liu G, Yan F, Ma X, Huang Z, et al. Body iron stores and heme-iron intake in relation to risk of type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2012; 7:e41641. PMID: 22848554.
Article
14. Aregbesola A, Voutilainen S, Virtanen JK, Mursu J, Tuomainen TP. Body iron stores and the risk of type 2 diabetes in middle-aged men. Eur J Endocrinol. 2013; 169:247–253. PMID: 23715774.
Article
15. Hatunic M, Finucane FM, Norris S, Pacini G, Nolan JJ. Glucose metabolism after normalization of markers of iron overload by venesection in subjects with hereditary hemochromatosis. Metabolism. 2010; 59:1811–1815. PMID: 20673928.
Article
16. Hramiak IM, Finegood DT, Adams PC. Factors affecting glucose tolerance in hereditary hemochromatosis. Clin Invest Med. 1997; 20:110–118. PMID: 9088667.
17. European Association For The Study Of The Liver. EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol. 2010; 53:3–22. PMID: 20471131.
18. Wood MJ, Skoien R, Powell LW. The global burden of iron overload. Hepatol Int. 2009; 3:434–444. PMID: 19669241.
Article
19. Phatak P, Brissot P, Wurster M, Adams PC, Bonkovsky HL, Gross J, et al. A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis. Hepatology. 2010; 52:1671–1679. PMID: 20814896.
Article
20. Stefashyna O, Stern M, Infanti L, Holbro A, Tichelli A, Buser A, et al. Pattern of care of blood donors with early-uncomplicated hereditary haemochromatosis in a Swiss blood donation centre. Vox Sang. 2014; 106:111–117. PMID: 23992555.
Article
Full Text Links
  • APEM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr